CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with its BCMA-targeting CAR T cell SYS-6020 for systemic lupus erythematosus (lupus) in China.
Scientists from Abbvie Inc. and the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center have discovered a new allosteric MALT1 inhibitor, ABBV-MALT1, for the treatment of certain types of diffuse large B-cell lymphoma (DLBCL).
LTZ Therapeutics Inc. has completed a series A financing of more than $20 million to advance the development of its myeloid engager pipeline to treat cancer and autoimmune diseases. The closing of this round brings LTZ’s total funding to about $50 million.
GSK plc and Flagship Pioneering Inc. have entered a collaboration to discover and develop a portfolio of therapeutics and vaccines for respiratory and immunology indications.
Parvus Therapeutics Inc.'s PVT-201 has received orphan drug status from the U.S. FDA for the treatment of primary biliary cholangitis (PBC), an autoimmune disease of the liver.
With $50 million in hand from Flagship Pioneering, Abiologics Inc. is pairing generative artificial intelligence with high-throughput chemical protein synthesis to attack oncology and immunology indications with Synteins, synthetic proteins that represent a new class of programmable medicines. Avak Kahvejian, co-founder and CEO of Abiologics and general partner at Flagship, told BioWorld that Abiologics stands “at the precipice of a completely new modality.”
Iaso Biotechnology Co. Ltd. has announced that China’s National Medical Products Administration (NMPA) has approved the IND application for IASO-782 injection for a new indication – systemic lupus erythematosus.
The symptoms of allergic rhinitis (AR), such as nasal congestion, runny nose or sneezing, start within minutes of allergen exposure after mast cells release mediators such as histamine, prostaglandins and leukotrienes.
Age-related inflammation, also known as inflammaging, refers to low-grade chronic damage caused by increased inflammation linked to immunosenescence with impact at molecular, cellular and tissue levels. Aging amplifies the inflammatory response and increases neutrophil, monocyte and leukocyte trafficking in models of inflammation.
The 2024 meeting of the International AIDS Society (IAS), which is being held in Munich this week, began with the announcement of another curative bone marrow transplant. The new case brings the total number of patients cured of HIV via a bone marrow transplant up to 7 since “Berlin patient” Timothy Ray Brown became the first such person in 2007.
RSS
